Polycystic ovary syndrome: can myo-inositol affect fertility outcomes?

This study investigated the effects of myo-inositol (MYO) on fertility outcomes in women with polycystic ovary syndrome (PCOS). 

They found that MYO was associated with improved embryo quality and fertilization rates.

Polycystic ovary syndrome (PCOS) is a common cause of infertility in women. In vitro fertilization (IVF) can be used to treat infertility. Many women with PCOS do not ovulate regularly. In PCOS there may be an excess in the production of hormones called androgens. These can interfere with ovulation. They can also cause insulin resistance. Insulin resistance is common in PCOS.

Myo-inositol (MYO) is a drug used to reduce insulin resistance. It is prescribed to many patients with PCOS. Some studies suggest that MYO treatment is associated with improved oocyte (egg) quality. However, it is unclear if MYO has an effect on fertility outcomes in patients with PCOS undergoing IVF. 

This study included 50 patients with PCOS undergoing IVF. Patients were randomly assigned to one of two groups. One group received 4 mg MYO and 400 mg folic acid daily. The other group received only folic acid. All patients underwent a standard protocol for ovarian stimulation and IVF. Oocyte quality and embryo quality were assessed before transfer to the womb.

The number of oocytes harvested was similar in both groups. However, the oocyte quality was significantly higher in the MYO group. Fertilization rates were also higher in the MYO group. Embryo quality was also significantly higher in MYO-treated patients. Pregnancy rates were similar between the groups (40% MYO vs. 35% control).

The authors concluded that MYO was associated with improved embryo quality and fertilization rates.

The number of patients in this study was relatively low. More investigation is needed to determine the effects of MYO on IVF.

If you have any concerns regarding fertility, please consult with your physician.